| Document Date: 2011-10-24 17:06:35
Open Document File Size: 347,74 KBShare Result on Facebook
City Socci / Holladay / Gregory / stem cell / Delivery Cell / Lee / Cowan / Mullen / / Company Draper / Thomson / John Wiley and Sons Ltd / / / Event Product Issues / / Facility Baylor College of Medicine / / IndustryTerm basic tools / insertion site / cellular machinery / bioprocess manufacturing capability / nuclear transfer technology / attractive potential tools / bank / clinical laboratory infrastructure / / MedicalCondition X-linked SCID / adenosine deaminase-deficient SCID / dysfunction / herpes / teratocarcinoma / polygenic diseases / X-linked severe combined immunodeficiency / injury / cystic fibrosis / MS / leukemia / inherited single gene defects / severe combined immunodeficiency / cancer / monogenic inherited diseases / disease / monogenic disorder / diseases / monogenic disorders / hypogammaglobulinemia / SCID / adenosine deaminase deficiency / deficiency / herpes simplex / / MedicalTreatment gene therapy / bypass / Cell therapy / / Organization Department of Molecular and Cellular Biology / Baylor College of Medicine / Houston / Center for Cell and Gene Therapy / / Person Terese Winslow / Thomas P. Zwaka / / Position Editor / mediator / PM / Kohn DB / Major / / Product ES / ganciclovir / adenosine / SCID / / ProvinceOrState Texas / North Dakota / British Columbia / Mississippi / California / / PublishedMedium Molecular and Cellular Biology / / Technology Cell therapy / transplantation / STEM CELLS / human genome / gene therapy / gene expression / gene targeting / Targeted gene knockout / recombination / nuclear transfer technology / recombinant DNA / / URL www.wiley.co.uk/genmed/clinical / /
SocialTag |
4. USE OF GENETICALLY MODIFIED STEM CELLS IN EXPERIMENTAL GENE THERAPIES by Thomas P. Zwaka* therapeutic strategies. The first successful clinical trials using gene therapy to treat a monogenic disorder